Alembic Pharmaceuticals Reports Net Profit of Rs 176 Crores in Q3FY22

India Branded business up 17%

Financial Highlights

• Net Sales for the quarter at Rs 1272 crores.
• Net Profit for the quarter at Rs 176 crores.
• Net sales for 9M FY22 at Rs 3890 crores.
• Net profit for 9M FY22 at Rs 510 crores.

New Delhi, February 11, 2022: Alembic Pharmaceuticals Limited today reported its consolidated financial results for the quarter ending 31^stDecember 2021. The net profit of the company stands at Rs 176 crores for this quarter with net sales at Rs 1272 crores. Net sales for the 9 month period (FY22) is at Rs 3890 crores with net profit during the same period at Rs 510 crores.

Mr. Shaunak Amin, Managing Director, Alembic Pharmaceuticals Limited said“India Branded business has posted a strong growth rate for the third consecutive quarter. Strong operational performance is attributed to consistent efforts of team and strengthening of customer relationships. Branded business witnessed market outperforming growth across most of the key products and therapy areas.”

Operational Highlights     

International Generics

• US Generics at Rs393 crores in the quarter and at Rs1109 Crores for 9M FY22.
• Ex-US International Formulations atRs 193 Crores in the quarter and at Rs587 Crores for 9M FY22.
• 6 ANDA filings during the quarter; Cumulative ANDA filings at 220.
• 4 ANDA approvals received during the quarter including 2 tentative; 154 Cumulative ANDA approvals including 20 tentative.

India Branded

• India Branded Business at Rs488 crores in the quarter and at Rs1478 crores in the 9M FY22.
• Acute & specialty segment grew faster than IPM.

 API

• API business atRs198 crores in the quarter and at Rs716 crores for 9M FY22.
• 1 DMF was filed in the quarter.

Summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q3 FY22	Q3 FY21	% Change	9M FY22	9M FY21	% Change
Formulation
USA Ex-US	393 193	512 171	(23%) 13%	1109 587	1689 544	(34%) 8%
India	488	418	17%	1478	1138	30%
API	198	214	(7%)	716	741	(3%)
Total	1272	1314	(3%)	3890	4113	(5%)

Summary of Profit is as under:      (Rs in Crores)

Particulars	Q3 FY22	Q3 FY21	% Change	9M FY22	9M FY21	% Change
EBITDA Pre R&D	406	536	(24%)	1233	1713	(28%)
EBITDA Pre R&D %	32%	41%		32%	42%
EBITDA Post R&D	269	401	(33%)	791	1272	(38%)
EBITDA Post R&D %	21%	31%		20%	31%
Profit Before Tax	209	352	(41%)	616	1126	(45%)
Net Profit after Tax	176	293	(40%)	510	927	(45%)

 

Corporate Comm India (CCI Newswire)